Published July 1, 2022 | Version Supplemental Material + Submitted
Discussion Paper Open

A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice

Abstract

Parkinson's disease (PD) is a movement disorder characterized by neuroinflammation, α-synuclein pathology, and neurodegeneration. Most cases of PD are non-hereditary, suggesting a strong role for environmental factors, and it has been speculated that disease may originate in peripheral tissues such as the gastrointestinal (GI) tract before affecting the brain. The gut microbiome is altered in PD and may impact motor and GI symptoms as indicated by animal studies, though mechanisms of gut-brain interactions remain incompletely defined. Intestinal bacteria ferment dietary fibers into short-chain fatty acids, with fecal levels of these molecules differing between PD and healthy controls and in mouse models. Among other effects, dietary microbial metabolites can modulate activation of microglia, brain-resident immune cells implicated in PD. We therefore investigated whether a fiber-rich diet influences microglial function in α-synuclein overexpressing (ASO) mice, a preclinical model with PD-like symptoms and pathology. Feeding a prebiotic high-fiber diet attenuates motor deficits and reduces α-synuclein aggregation in the substantia nigra of mice. Concomitantly, the gut microbiome of ASO mice adopts a profile correlated with health upon prebiotic treatment, which also reduces microglial activation. Single-cell RNA-seq analysis of microglia from the substantia nigra and striatum uncovers increased pro-inflammatory signaling and reduced homeostatic responses in ASO mice compared to wild-type counterparts on standard diets. However, prebiotic feeding reverses pathogenic microglial states in ASO mice and promotes expansion of protective disease-associated macrophage (DAM) subsets of microglia. Notably, depletion of microglia using a CSF1R inhibitor eliminates the beneficial effects of prebiotics by restoring motor deficits to ASO mice despite feeding a prebiotic diet. These studies uncover a novel microglia-dependent interaction between diet and motor symptoms in mice, findings that may have implications for neuroinflammation and PD.

Additional Information

The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. We thank members of the Mazmanian laboratory and Dr. Catherine Oikonomou for critical review of this manuscript. We thank the Caltech Office of Laboratory Animal Research (OLAR) for animal husbandry, Dr. Wei-Li Wu for assistance with SCFA brain measurements, Dr. Sisi Chen and the Caltech Single-Cell Profiling and Engineering Center (SPEC) for technical assistance and support, the Caltech Flow Cytometry and Cell Sorting Facility for technical assistance, the Caltech Bioinformatics Center for data analysis support, and the Caltech Biological Imaging Facility (BIF) for training and use of confocal microscopes. We thank Prof. Chen-Chih Hsu's laboratory in the Department of Chemistry at National Taiwan University and BIOTOOLS Co., Ltd. for the feces and brain SCFA measurements. R.A. was supported by the U.S. Department of Defense, the Donna and Benjamin M. Rosen Bioengineering Center, and the Biotechnology Leadership Program at Caltech. This study was funded by grants to S.K.M. from the U.S. Department of Defense (PD160030), Heritage Medical Research Institute (HMRI-15-09-01), and by the joint efforts of the Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Aligning Science Across Parkinson's (ASAP) initiative. MJFF administers the grant (ASAP-000375) on behalf of ASAP and itself. Data Availability. All datasets generated or analyzed in this study can be found through the Zenodo depository: https://doi.org/10.5281/zenodo.6377704 All experimental protocols can be found on protocols.io. Competing Interests. A.K., T.C-J., and B.R.H. have equity in RiteCarbs, a company developing prebiotic diets for Parkinson's disease. S.K.M. has equity in Axial Therapeutics, a company developing gut-restricted drugs for Parkinson's disease.

Attached Files

Submitted - 2022.06.27.497828v1.full.pdf

Supplemental Material - media-1.xlsx

Supplemental Material - media-2.xlsx

Supplemental Material - media-3.xlsx

Files

2022.06.27.497828v1.full.pdf

Files (8.1 MB)

Name Size Download all
md5:06b9d51a9f3e25b74ac6e2dd5d4c0746
7.8 MB Preview Download
md5:1ef01cf58706772799c78df4eb6884bb
17.6 kB Download
md5:67695bf7b0063e18862193f6c50fb7a0
207.1 kB Download
md5:fca56d7e9e53b61d7b785314caab99c3
52.4 kB Download

Additional details

Identifiers

Eprint ID
115357
Resolver ID
CaltechAUTHORS:20220706-965670000

Funding

Department of Defense
PD160030
Donna and Benjamin M. Rosen Bioengineering Center
Caltech Biotechnology Leadership Program
Heritage Medical Research Institute
HMRI-15-09-01
Michael J. Fox Foundation
Aligning Science Across Parkinson's
ASAP-000375

Dates

Created
2022-07-08
Created from EPrint's datestamp field
Updated
2022-12-06
Created from EPrint's last_modified field

Caltech Custom Metadata

Caltech groups
Rosen Bioengineering Center, Heritage Medical Research Institute, Division of Biology and Biological Engineering (BBE), Division of Biology and Biological Engineering (BBE), Division of Biology and Biological Engineering (BBE)